Response to Schwarz C.W., et al. 'Comparative 2-year drug survival of bimekizumab and brodalumab in second-line treatment of psoriasis'.
Spangenberg A, Koo JYM
Journal of the American Academy of DermatologyIn the feed 6 Oct 2026, published online 6 Oct 2026, issue 2026 Oct 06, added to PubMed 6 Oct 2026
Topics: Psoriasis
Abstract
PubMed has no abstract for this paper, as is usual for research letters, correspondence and editorials. The publisher’s page has the full paper.
PMID 42838225 · DOI 10.1016/j.jaad.2026.07.143